Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Mostrar otras versiones (1)
Detalles Bibliográficos
Autores principales: Jiang, Qian, Li, Zongru, Qin, Yazhen, Li, Weiming, Xu, Na, Liu, Bingcheng, Zhang, Yanli, Meng, Li, Zhu, Huanling, Du, Xin, Chen, Suning, Liang, Yang, Hu, Yu, Liu, Xiaoli, Song, Yongping, Men, Lichuang, Chen, Zi, Niu, Qian, Wang, Hengbang, Lu, Ming, Yang, Dajun, Zhai, Yifan, Huang, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623999/
https://www.ncbi.nlm.nih.gov/pubmed/36316695
http://dx.doi.org/10.1186/s13045-022-01369-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623999/
https://www.ncbi.nlm.nih.gov/pubmed/36316695
http://dx.doi.org/10.1186/s13045-022-01369-2

Ejemplares similares